Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
News
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia,…
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia,…
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — INmune Bio (NASDAQ: INMB), a clinical-stage…
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — INmune Bio (NASDAQ: INMB), a clinical-stage…
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”),…
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”),…
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or…
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or…
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative…
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative…
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September…
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September…
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial…